Oppenheimer


Oppenheimer Remains Bullish On Chemed Following Meetings With Management; Raises PT To $115

In a research report issued today, Oppenheimer analyst Michael Wiederhorn maintained an Outperform rating on Chemed (NYSE:CHE) and raised his price target to $115 …

Oppenheimer Maintains Outperform On Ascena Retail, Reduces PT To $19

In a research report issued today, Oppenheimer analyst Anna Andreeva maintained an Outperform rating on Ascena Retail (NASDAQ:ASNA), and reduced his price target …

Oppenheimer Maintains Buy On Yahoo!; Raises Price Target To $48 On Alibaba Public Valuation

In a research report issued today, Oppenheimer analyst Jason Helfstein maintained a Buy rating on Yahoo! Inc.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts